Upstream Bio to Present Novel TSLP Antagonist Verekitug at Goldman Sachs Healthcare Conference
Key Insights
Upstream Bio (search) will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, featuring their clinical-stage inflammatory disease treatments.
The company is developing verekitug, the only known TSLP (search) receptor antagonist currently in clinical development, targeting a validated driver of inflammatory response.
Verekitug has advanced to separate Phase 2 trials for chronic rhinosinusitis with nasal polyps (search), severe asthma (search), and chronic obstructive pulmonary disease (search).
Upstream Bio (search), a clinical-stage biotechnology company developing treatments for inflammatory diseases (search), announced that CEO Rand Sutherland, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 10:40 a.m. ET.
Unique TSLP Targeting Approach
The company is developing verekitug, described as the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (search) (TSLP (search)). TSLP is a cytokine identified as a clinically validated driver of inflammatory response, positioned upstream of multiple signaling cascades that affect various immune-mediated diseases.
Advanced Clinical Development Program
Upstream Bio (search) has advanced this highly potent monoclonal antibody into separate Phase 2 trials across three respiratory conditions:
- Chronic rhinosinusitis with nasal polyps (CRSwNP)
- Severe asthma
- Chronic obstructive pulmonary disease (COPD)
Addressing Unmet Medical Needs
The company's team is committed to maximizing verekitug's unique attributes to address substantial unmet needs for patients underserved by current standard of care treatments. The focus on severe respiratory disorders represents Upstream Bio (search)'s initial therapeutic area of concentration within the broader inflammatory disease space.
Conference Details
A live webcast of the presentation will be available under the Events tab on the Investors section of Upstream Bio (search)'s website on the day of the event. A replay will be available on the company's website following the presentation.
The Goldman Sachs conference represents a key opportunity for Upstream Bio (search) to present their differentiated approach to inflammatory disease treatment through TSLP (search) receptor antagonism to the investment community.